Lead sponsor
Peptron, Inc.
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
2
Trials led
0
Active
133
Total enrollment
5
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Completed
1
Unknown
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease—Ph 2Unknown99
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) ExenatideMale · Healthy volunteersPh 1Completed34